1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1): 5-29.
|
2. |
刘文, 程若川. 甲状腺乳头状癌中央区淋巴结转移的预测因素. 中国普外基础与临床杂志, 2018, 25(1): 99-103.
|
3. |
Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1(PD-1) and PD-ligand 1(PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7(2): 1486-1499.
|
4. |
Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol, 2016, 27(3): 409-416.
|
5. |
鄢敏, 李德智, 别俊. 程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂治疗食管癌的进展. 华西医学, 2020, 35(10): 1267-1272.
|
6. |
王亚东, 杨笑盈, 贾梓淇, 等. 循环肿瘤细胞PD-L1表达在非小细胞肺癌免疫治疗中的应用. 中国胸心血管外科临床杂志, 2021, 28(1): 110-115.
|
7. |
刘敏龙, 王国恩, 张军. 程序性细胞死亡因子配体1在轻型和重型脓毒症小鼠单核细胞的表达和差异. 中国呼吸与危重监护杂志, 2015, 14(4): 358-361.
|
8. |
Fadia M, Fookeerah P, Ali S, et al. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology, 2020, 52(3): 318-322.
|
9. |
Loos M, Giese NA, Kleeff J, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett, 2008, 268(1): 98-109.
|
10. |
Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg, 2005, 71(10): 874-878.
|
11. |
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 2006, 295(18): 2164-2167.
|
12. |
Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg, 1955, 70(2): 291-297.
|
13. |
Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? Review J Clin Endocrinol Metab, 2013, 98(2): 474-482.
|
14. |
Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol, 2002, 10(2): 141-146.
|
15. |
Eisenberg BL, Hensley SD. Thyroid cancer with coexistent Hashimoto’s thyroiditis. Clinical assessment and management. Arch Surg, 1989, 124(9): 1045-1047.
|
16. |
Schäffler A, Palitzsch KD, Seiffarth C, et al. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest, 1998, 28(10): 838-844.
|
17. |
Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol, 2017, 12(2): 208-222.
|
18. |
Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget, 2016, 7(22): 32318-32328.
|
19. |
Han LT, Hu JQ, Ma B, et al. IL-17A increases MHC class Ⅰ expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto’s thyroiditis. Diagn Pathol, 2019, 14(1): 52.
|
20. |
Hu JQ, Lei BW, Wen D, et al. IL-2 enhanced MHC class Ⅰexpression in papillary thyroid cancer with Hashimoto’s thyroiditis overcomes immune escape in vitro. J Cancer, 2020, 11(14): 4250-4260.
|
21. |
Bai Y, Niu D, Huang X, et al. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagn Pathol, 2017, 12(1): 72.
|
22. |
Lubin D, Baraban E, Lisby A, et al. Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis. Endocr Pathol, 2018, 29(4): 317-323.
|